Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Anti-Peptic Ulcer Drugs Market by Type (Proton Pump Inhibitors (PPIs), Potassium-Competitive Acid Blockers (P-CAB), Antacids, H2 Antagonists, Ulcer Protective Drugs), By Application (Gastritis, Gastric Ulcers, Duodenal Ulcers, Gastroesophageal Reflux Disease (GERD)) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Anti-Peptic Ulcer Drugs Market by Type (Proton Pump Inhibitors (PPIs), Potassium-Competitive Acid Blockers (P-CAB), Antacids, H2 Antagonists, Ulcer Protective Drugs), By Application (Gastritis, Gastric Ulcers, Duodenal Ulcers, Gastroesophageal Reflux Disease (GERD)) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 171064 3300 Pharma & Healthcare 377 245 Pages 4.9 (49)
                                          

Industry Growth Insights published a new data on “Anti-Peptic Ulcer Drugs Market”. The research report is titled “Anti-Peptic Ulcer Drugs Market research by Types (Proton Pump Inhibitors (PPIs), Potassium-Competitive Acid Blockers (P-CAB), Antacids, H2 Antagonists, Ulcer Protective Drugs), By Applications (Gastritis, Gastric Ulcers, Duodenal Ulcers, Gastroesophageal Reflux Disease (GERD)), By Players/Companies AstraZeneca, Ask-pharm, Takeda, Yangtze River Pharm, Shandong Luoxin, Huadong Medicine, Changzhou Siyao, Beijing Yuekang, Guangdong Dahua, Xian Janssen”.

Scope Of The Report

Report Attributes

Report Details

Report Title

Anti-Peptic Ulcer Drugs Market Research Report

By Type

Proton Pump Inhibitors (PPIs), Potassium-Competitive Acid Blockers (P-CAB), Antacids, H2 Antagonists, Ulcer Protective Drugs

By Application

Gastritis, Gastric Ulcers, Duodenal Ulcers, Gastroesophageal Reflux Disease (GERD)

By Companies

AstraZeneca, Ask-pharm, Takeda, Yangtze River Pharm, Shandong Luoxin, Huadong Medicine, Changzhou Siyao, Beijing Yuekang, Guangdong Dahua, Xian Janssen

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

245

Number of Tables & Figures

172

Customization Available

Yes, the report can be customized as per your need.


Global Anti-Peptic Ulcer Drugs Industry Outlook


Global Anti-Peptic Ulcer Drugs Market Report Segments:

The global Anti-Peptic Ulcer Drugs market is segmented on the basis of:

Types

Proton Pump Inhibitors (PPIs), Potassium-Competitive Acid Blockers (P-CAB), Antacids, H2 Antagonists, Ulcer Protective Drugs

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Gastritis, Gastric Ulcers, Duodenal Ulcers, Gastroesophageal Reflux Disease (GERD)

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. AstraZeneca
  2. Ask-pharm
  3. Takeda
  4. Yangtze River Pharm
  5. Shandong Luoxin
  6. Huadong Medicine
  7. Changzhou Siyao
  8. Beijing Yuekang
  9. Guangdong Dahua
  10. Xian Janssen

Global Anti-Peptic Ulcer Drugs Market Overview


Highlights of The Anti-Peptic Ulcer Drugs Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Proton Pump Inhibitors (PPIs)
    2. Potassium-Competitive Acid Blockers (P-CAB)
    3. Antacids
    4. H2 Antagonists
    5. Ulcer Protective Drugs
  1. By Application:

    1. Gastritis
    2. Gastric Ulcers
    3. Duodenal Ulcers
    4. Gastroesophageal Reflux Disease (GERD)
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Anti-Peptic Ulcer Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Anti-Peptic Ulcer Drugs Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


Anti-peptic ulcer drugs are medications used to treat ulcers. These drugs work by reducing the amount of acid that is produced in the stomach.

Some of the major players in the anti-peptic ulcer drugs market are AstraZeneca, Ask-pharm, Takeda, Yangtze River Pharm, Shandong Luoxin, Huadong Medicine, Changzhou Siyao, Beijing Yuekang, Guangdong Dahua, Xian Janssen.

                                            
1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Anti-Peptic Ulcer Drugs Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Anti-Peptic Ulcer Drugs Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Anti-Peptic Ulcer Drugs Market - Supply Chain
   4.5. Global Anti-Peptic Ulcer Drugs Market Forecast
      4.5.1. Anti-Peptic Ulcer Drugs Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Anti-Peptic Ulcer Drugs Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Anti-Peptic Ulcer Drugs Market Absolute $ Opportunity

5. Global Anti-Peptic Ulcer Drugs Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Anti-Peptic Ulcer Drugs Market Size and Volume Forecast by Type
      5.3.1. Proton Pump Inhibitors (PPIs)
      5.3.2. Potassium-Competitive Acid Blockers (P-CAB)
      5.3.3. Antacids
      5.3.4. H2 Antagonists
      5.3.5. Ulcer Protective Drugs
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Anti-Peptic Ulcer Drugs Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Anti-Peptic Ulcer Drugs Market Size and Volume Forecast by Application
      6.3.1. Gastritis
      6.3.2. Gastric Ulcers
      6.3.3. Duodenal Ulcers
      6.3.4. Gastroesophageal Reflux Disease (GERD)
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Anti-Peptic Ulcer Drugs Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Anti-Peptic Ulcer Drugs Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Anti-Peptic Ulcer Drugs Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Anti-Peptic Ulcer Drugs Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Anti-Peptic Ulcer Drugs Demand Share Forecast, 2019-2026

9. North America Anti-Peptic Ulcer Drugs Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Anti-Peptic Ulcer Drugs Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Anti-Peptic Ulcer Drugs Market Size and Volume Forecast by Application
      9.4.1. Gastritis
      9.4.2. Gastric Ulcers
      9.4.3. Duodenal Ulcers
      9.4.4. Gastroesophageal Reflux Disease (GERD)
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Anti-Peptic Ulcer Drugs Market Size and Volume Forecast by Type
      9.7.1. Proton Pump Inhibitors (PPIs)
      9.7.2. Potassium-Competitive Acid Blockers (P-CAB)
      9.7.3. Antacids
      9.7.4. H2 Antagonists
      9.7.5. Ulcer Protective Drugs
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Anti-Peptic Ulcer Drugs Demand Share Forecast, 2019-2026

10. Latin America Anti-Peptic Ulcer Drugs Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Anti-Peptic Ulcer Drugs Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Anti-Peptic Ulcer Drugs Market Size and Volume Forecast by Application
      10.4.1. Gastritis
      10.4.2. Gastric Ulcers
      10.4.3. Duodenal Ulcers
      10.4.4. Gastroesophageal Reflux Disease (GERD)
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Anti-Peptic Ulcer Drugs Market Size and Volume Forecast by Type
      10.7.1. Proton Pump Inhibitors (PPIs)
      10.7.2. Potassium-Competitive Acid Blockers (P-CAB)
      10.7.3. Antacids
      10.7.4. H2 Antagonists
      10.7.5. Ulcer Protective Drugs
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Anti-Peptic Ulcer Drugs Demand Share Forecast, 2019-2026

11. Europe Anti-Peptic Ulcer Drugs Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Anti-Peptic Ulcer Drugs Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Anti-Peptic Ulcer Drugs Market Size and Volume Forecast by Application
      11.4.1. Gastritis
      11.4.2. Gastric Ulcers
      11.4.3. Duodenal Ulcers
      11.4.4. Gastroesophageal Reflux Disease (GERD)
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Anti-Peptic Ulcer Drugs Market Size and Volume Forecast by Type
      11.7.1. Proton Pump Inhibitors (PPIs)
      11.7.2. Potassium-Competitive Acid Blockes (P-CAB)
      11.7.3. Antacids
      11.7.4. H2 Antagonists
      11.7.5. Ulcer Protective Drugs
   11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Anti-Peptic Ulcer Drugs Demand Share, 2019-2026

12. Asia Pacific Anti-Peptic Ulcer Drugs Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Anti-Peptic Ulcer Drugs Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Anti-Peptic Ulcer Drugs Market Size and Volume Forecast by Application
      12.4.1. Gastritis
      12.4.2. Gastric Ulcers
      12.4.3. Duodenal Ulcers
      12.4.4. Gastroesophageal Reflux Disease (GERD)
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Anti-Peptic Ulcer Drugs Market Size and Volume Forecast by Type
      12.7.1. Proton Pump Inhibitors (PPIs)
      12.7.2. Potassium-Competitive Acid Blockers (P-CAB)
      12.7.3. Antacids
      12.7.4. H2 Antagonists
      12.7.5. Ulcer Protective Drugs
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Anti-Peptic Ulcer Drugs Demand Share, 2019-2026

13. Middle East & Africa Anti-Peptic Ulcer Drugs Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Anti-Peptic Ulcer Drugs Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Anti-Peptic Ulcer Drugs Market Size and Volume Forecast by Application
      13.4.1. Gastritis
      13.4.2. Gastric Ulcers
      13.4.3. Duodenal Ulcers
      13.4.4. Gastroesophageal Reflux Disease (GERD)
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Anti-Peptic Ulcer Drugs Market Size and Volume Forecast by Type
      13.7.1. Proton Pump Inhibitors (PPIs)
      13.7.2. Potassium-Competitive Acid Blockers (P-CAB)
      13.7.3. Antacids
      13.7.4. H2 Antagonists
      13.7.5. Ulcer Protective Drugs
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Anti-Peptic Ulcer Drugs Demand Share, 2019-2026

14. Competition Landscape
   14.1. Global Anti-Peptic Ulcer Drugs Market: Market Share Analysis
   14.2. Anti-Peptic Ulcer Drugs Distributors and Customers
   14.3. Anti-Peptic Ulcer Drugs Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. AstraZeneca
         14.4.1.1. Overview
         14.4.1.2. Financials
         14.4.1.3. Developments
         14.4.1.4. Strategic Outlook
      14.4.2. Ask-pharm
         14.4.2.1. Overview
         14.4.2.2. Financials
         14.4.2.3. Developments
         14.4.2.4. Strategic Outlook
      14.4.3. Takeda
         14.4.3.1. Overview
         14.4.3.2. Financials
         14.4.3.3. Developments
         14.4.3.4. Strategic Outlook
      14.4.4. Yangtze River Pharm
         14.4.4.1. Overview
         14.4.4.2. Financials
         14.4.4.3. Developments
         14.4.4.4. Strategic Outlook
      14.4.5. Shandong Luoxin
         14.4.5.1. Overview
         14.4.5.2. Financials
         14.4.5.3. Developments
         14.4.5.4. Strategic Outlook
      14.4.6. Huadong Medicine
         14.4.6.1. Overview
         14.4.6.2. Financials
         14.4.6.3. Developments
         14.4.6.4. Strategic Outlook
      14.4.7. Changzhou Siyao
         14.4.7.1. Overview
         14.4.7.2. Financials
         14.4.7.3. Developments
         14.4.7.4. Strategic Outlook
      14.4.8. Beijing Yuekang
         14.4.8.1. Overview
         14.4.8.2. Financials
         14.4.8.3. Developments
         14.4.8.4. Strategic Outlook
      14.4.9. Guangdong Dahua
         14.4.9.1. Overview
         14.4.9.2. Financials
         14.4.9.3. Developments
         14.4.9.4. Strategic Outlook
      14.4.10. Xian Janssen
         14.4.10.1. Overview
         14.4.10.2. Financials
         14.4.10.3. Developments
         14.4.10.4. Strategic Outlook
      14.4.11. COMPANY 11
         14.4.11.1. Overview
         14.4.11.2. Financials
         14.4.11.3. Developments
         14.4.11.4. Strategic Outlook
      14.4.12. COMPANY 12
         14.4.12.1. Overview
         14.4.12.2. Financials
         14.4.12.3. Developments
         14.4.12.4. Strategic Outlook
      14.4.13. COMPANY 13
         14.4.13.1. Overview
         14.4.13.2. Financials
         14.4.13.3. Developments
         14.4.13.4. Strategic Outlook
      14.4.14. COMPANY 14
         14.4.14.1. Overview
         14.4.14.2. Financials
         14.4.14.3. Developments
         14.4.14.4. Strategic Outlook
      14.4.15. COMPANY 15
         14.4.15.1. Overview
         14.4.15.2. Financials
         14.4.15.3. Developments
         14.4.15.4. Strategic Outlook
      14.4.16. COMPANY 16
         14.4.16.1. Overview
         14.4.16.2. Financials
         14.4.16.3. Developments
         14.4.16.4. Strategic Outlook
      14.4.17. COMPANY 17
         14.4.17.1. Overview
         14.4.17.2. Financials
         14.4.17.3. Developments
         14.4.17.4. Strategic Outlook
      14.4.18. COMPANY 18
         14.4.18.1. Overview
         14.4.18.2. Financials
         14.4.18.3. Developments
         14.4.18.4. Strategic Outlook
      14.4.19. COMPANY 19
         14.4.19.1. Overview
         14.4.19.2. Financials
         14.4.19.3. Developments
         14.4.19.4. Strategic Outlook
      14.4.20. COMPANY 20
         14.4.20.1. Overview
         14.4.20.2. Financials
         14.4.20.3. Developments
         14.4.20.4. Strategic Outlook

Our Trusted Clients

Contact Us